Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 1/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.46 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| At-9010 SCHEMBL18067079 | 1.00 | GPR17 (0.52) | GPR17P2RX3P2RY1P2RX1P2RX4 | |
| SCHEMBL18067078 | 0.99 | GPR17 (0.51) | GPR17P2RX3P2RY1P2RX1P2RX4 | |
| SCHEMBL18067076 | 0.93 | P2RY1 (0.51) | P2RY1ADORA3ADORA1NT5EADORA2B | |
| SCHEMBL26025244 | 0.91 | GPR17 (0.53) | GPR17P2RX3P2RY1P2RX1P2RX4 | |
| SCHEMBL21136121 | 0.91 | GPR17 (0.54) | GPR17P2RX3P2RY1P2RX1P2RX4 | |
| SCHEMBL18061567 | 0.91 | P2RY1 (0.55) | GPR17P2RX3P2RY1P2RX1P2RX4 | |
| SCHEMBL21136165 | 0.91 | GPR17 (0.51) | GPR17P2RX3P2RY1P2RX1P2RX4 | |
| SCHEMBL26025255 | 0.90 | GPR17 (0.52) | GPR17P2RX3P2RY1P2RX1P2RX4 | |
| SCHEMBL21136119 | 0.90 | GPR17 (0.53) | GPR17P2RX3P2RY1P2RX1P2RX4 | |
| SCHEMBL18061584 | 0.90 | P2RY1 (0.55) | GPR17P2RX3P2RY1P2RX1P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238324-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2024-07-18 | — | — | US | disclosed |
| US-11707480-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707480-B2 | Highly active compounds against COVID-19 | PNP, MTAP, ACE2 | GPR17 263/4885P2RX3 122/4885P2RY1 40/4885 |
| US-20240238324-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | PNP, MTAP, ACE2 | GPR17 263/4885P2RX3 122/4885P2RY1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.